Replies to post #163938 on Biotech Values

[oc631]

There are no GT1a in Russia, only GT1b, while in the US the split is ~80/20 in favor of GT1a.

I'm not sure how you can say there's no GT1A patients in Russia. Regardless there's no late-stage data in GT1B to support this filing.